Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
03.04.2023 - Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors ...
United States Thomasg Wiggans Pardes Biosciences Company Annual Report On Form Drug Administration Company Board Of Directors
Source: wallstreet-online.de